LDS/Medical Tests/Hereditary Colon Cancer Gene Mutation Panel (Lynch syndrome), NGS

Hereditary Colon Cancer Gene Mutation Panel (Lynch syndrome), NGS

A hereditary colon cancer gene mutation panel detects somatic and germline mutations that have been identified in colorectal cancer (CRC). CRC is one of the most common cancers worldwide and approximately 5-10% of cases are due to an inherited predisposition. Hereditary CRC syndromes can be divided into non-polyposis syndromes and polyposis syndromes. The most common form of hereditary CRC is Lynch syndrome (also known as hereditary non-polyposis colorectal cancer, HNPCC) and familial adenomatous polyposis (FAP). However, there are multiple other genes that are present in CRC or contribute to an increased risk for colorectal cancer.

Lynch syndrome is an autosomal dominant syndrome caused by mutations in mismatch repair genes, mainly MLH1, MSH2, PMS2 and MSH6. It is estimated to account for 5% of all CRCs. Patients with MLH1 or MSH2 have approximately 50 – 80% lifetime risk of developing CRC and women have approximately 40% lifetime risk of developing endometrial cancer.

Familial adenomatous polyposis (FAP) is characterized by the development of hundreds or thousands of adenomatous polyps throughout the colon. In untreated cases, all FAP patients have high risk of developing CRC by the age of 35-40 years. FAP is caused by germline mutations in the APC gene and affects approximately 1 in 10,000 individuals. FAP is estimated to be responsible for 0.5-1% of all CRC cases. FAP patients may display extracolonic features such as papillary thyroid carcinoma and hepatoblastomas.

Other rarer CRC predisposition syndromes include MUTYH-associated polyposis (MAP), Peutz-Jeghers syndrome (PJS), juvenile polyposis (JPS), and Cowden syndrome. The phenotype in MAP resembles that in FAP, but patients tend to develop fewer polyps (5-100) and are diagnosed at an older age. MAP is caused by biallelic germline mutations in the MUTYH gene. In PJS, intestinal hamartomatous polyps are most commonly located in the small bowel but may also occur anywhere along approximately 1 in 200,000 individuals. JPS are characterized by multiple hamartomatous polyps in the colon and rectum. Patients with JPS have an increased risk of colon, gastric, small intestine, and pancreatic cancers. JPS is caused by the mutation in SMAD4 and BMPR1A genes. The prevalence is estimated at 1:100,000.

Cowden syndrome is characterized by multiple hamartomatous tumors of the skin, intestines, breast, and thyroid gland. Germline mutations in PTEN have been described in 80% of Cowden syndrome patients. People with CDH1 gene mutations associated with hereditary diffuse gastric cancer (HDGC) have a 56 to 70 percent chance of developing stomach (gastric) cancer in their lifetimes.

Panel Components

Although it depends on the laboratory and the clinical utility this panel uses targeted next-generation sequencing to evaluate for most common variants within genes:

Somatic mutations in Colon Cancer: BRAF, KRAS, NRAS, NTRK

Germline mutations associated with increased risk of colon cancer: APC, MUTYH, BMPR1A, MLH1, MSH2, MSH6, PMS2, EPCAM, PTEN, STK11, SMAD4, TP53, GREM1, POLD1, POLE, AXIN2, NTHL1, MSH3

  • As an aid in diagnosis of hereditary colon cancer in patients with a personal or family history suggestive of a hereditary colon cancer syndrome
  • Serves as supportive testing in increased risk for Lynch syndrome (e.g. microsatellite instability and/or lack of immunohistochemistry staining for a mismatch repair protein) cases
  • For patients with multiple cancers of the same origin (such as two separate colorectal cancers) or of different origin (such as colon and endometrial cancer in the same individual)
  • For evaluating families in which multiple relatives have been diagnosed with the same or related cancers (such as colon, endometrial, ovarian, urinary tract, gastric
  • For identifying mutations within genes known to be associated with increased risk for colon cancer allowing for predictive testing of at-risk family members
At least one known pathogenic variant or mutation associated with hereditary colon cancer should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.

Negative for mutations or pathogenic variants analyzed

Targeted Next-Generation Sequencing Followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing and Gene Dosage Analysis by Array Comparative Genomic Hybridization (aCGH) or Multiplex Ligation-Dependent Probe Amplification (MLPA).

Whole blood (EDTA).

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7 days
Colon biopsy, Microsatellite instability testing, methylation on specific markers for colon cancer.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Colorectal Cancer. 2018;17: e293-e305. [PMID: 29454559]
  • JAMA Oncol. 2015;1: 23-32. [PMID: 26182300]
  • Cancer J. 2012;18: 328-33. [PMID: 22846733]
  • JAMA. 2011;305: 2304-10. [PMID: 21642682]
  • Genet Med. 2010;12(4 Suppl):S15-38. [PMID: 20393305]
  • Am J Gastroenterol. 2010;105:2449-56. [PMID: 20531397]
  • J Natl Cancer Inst. 2010 Feb;102(3):193-201. [PMID: 20028993]
  • Clin Gastroenterol Hepatol. 2007;5: 379–87. [PMID: 17368238]
  • Lindor NM, McMaster ML, Lindor CJ, et al: Concise Handbook of Familial Cancer Susceptibility Syndromes. Second edition. J Natl Cancer Inst Monogr 2008;(38):1-93
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login